Antiphospholipid Antibodies As Key Players in Systemic Lupus Erythematosus: The Relationship with Cytokines and Immune Dysregulation

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Oct 26

PMID 39457063

Authors

Patricia Richter

Minerva Codruta Badescu

Ciprian Rezus

Anca Ouatu

Nicoleta Dima

Diana Popescu

Alexandra Maria Burlui

Ioana Bratoiu

Ioana Ruxandra Mihai

Elena Rezus

Affiliations

Soon will be listed here.

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by an overproduction of cytokines, such as interleukins and interferons, contributing to systemic inflammation and tissue damage. Antiphospholipid syndrome is a thrombo-inflammatory autoimmune disease affecting a third of SLE patients. We performed an in-depth analysis of the available literature, and we highlighted the complex interplay between immunity, inflammation, and thrombosis, the three major pathogenic pathways that are trapped in a mutually reinforcing destructive loop.

References

Farzaneh-Far A, Roman M, Lockshin M, Devereux R, Paget S, Crow M . Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum. 2006; 54(12):3918-25. DOI: 10.1002/art.22265. View

Yelnik C, Lambert M, Drumez E, Martin C, Grolaux G, Launay D . Relevance of inflammatory and complement activation biomarkers profiling in antiphospholipid syndrome patients outside acute thrombosis. Clin Exp Rheumatol. 2023; 41(9):1875-1881. DOI: 10.55563/clinexprheumatol/ric86c. View

Sene D, Piette J, Cacoub P . Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun Rev. 2008; 7(4):272-7. DOI: 10.1016/j.autrev.2007.10.001. View

Vinuesa C, Rigby R, Yu D . Logic and extent of miRNA-mediated control of autoimmune gene expression. Int Rev Immunol. 2009; 28(3-4):112-38. DOI: 10.1080/08830180902934909. View

Canaud G, Bienaime F, Tabarin F, Bataillon G, Seilhean D, Noel L . Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med. 2014; 371(4):303-12. DOI: 10.1056/NEJMoa1312890. View

Reshetnyak T, Nurbaeva K . The Role of Neutrophil Extracellular Traps (NETs) in the Pathogenesis of Systemic Lupus Erythematosus and Antiphospholipid Syndrome. Int J Mol Sci. 2023; 24(17). PMC: 10487763. DOI: 10.3390/ijms241713581. View

Urbanus R, de Laat H, de Groot P, Derksen R . Prolonged bleeding time and lupus anticoagulant: a second paradox in the antiphospholipid syndrome. Arthritis Rheum. 2004; 50(11):3605-9. DOI: 10.1002/art.20586. View

Fernandez Matilla M, Grau Garcia E, Fernandez-Llanio Comella N, Chalmeta Verdejo I, Cortes J, Castellano Cuesta J . Increased interferon-1α, interleukin-10 and BLyS concentrations as clinical activity biomarkers in systemic lupus erythematosus. Med Clin (Barc). 2019; 153(6):225-231. DOI: 10.1016/j.medcli.2018.12.012. View

Coenen C, Hidalgo T, Lynn T, Jones D, Salmon J, Chamley L . Antiphospholipid-exposed trophoblast-derived extracellular vesicles express elevated levels of TLR7/8-activating microRNAs and induce endometrial endothelial activation, in part, through TLR7. J Reprod Immunol. 2024; 164:104255. DOI: 10.1016/j.jri.2024.104255. View

10.

van den Hoogen L, Palla G, Bekker C, Fritsch-Stork R, Radstake T, van Roon J . Increased B-cell activating factor (BAFF)/B-lymphocyte stimulator (BLyS) in primary antiphospholipid syndrome is associated with higher adjusted global antiphospholipid syndrome scores. RMD Open. 2018; 4(2):e000693. PMC: 6045704. DOI: 10.1136/rmdopen-2018-000693. View

11.

Pisetsky D . The role of innate immunity in the induction of autoimmunity. Autoimmun Rev. 2008; 8(1):69-72. DOI: 10.1016/j.autrev.2008.07.028. View

12.

Sacharidou A, Shaul P, Mineo C . New Insights in the Pathophysiology of Antiphospholipid Syndrome. Semin Thromb Hemost. 2017; 44(5):475-482. PMC: 6333209. DOI: 10.1055/s-0036-1597286. View

13.

McNeil H, Simpson R, Chesterman C, Krilis S . Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990; 87(11):4120-4. PMC: 54059. DOI: 10.1073/pnas.87.11.4120. View

14.

Bodewes I, Al-Ali S, van Helden-Meeuwsen C, Maria N, Tarn J, Lendrem D . Systemic interferon type I and type II signatures in primary Sjögren's syndrome reveal differences in biological disease activity. Rheumatology (Oxford). 2018; 57(5):921-930. DOI: 10.1093/rheumatology/kex490. View

15.

Mockel T, Basta F, Weinmann-Menke J, Schwarting A . B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE). Autoimmun Rev. 2020; 20(2):102736. DOI: 10.1016/j.autrev.2020.102736. View

16.

Li S, Ren J, Xu N, Zhang J, Geng Q, Cao C . MicroRNA-19b functions as potential anti-thrombotic protector in patients with unstable angina by targeting tissue factor. J Mol Cell Cardiol. 2014; 75:49-57. DOI: 10.1016/j.yjmcc.2014.06.017. View

17.

Dabit J, Valenzuela-Almada M, Vallejo-Ramos S, Duarte-Garcia A . Epidemiology of Antiphospholipid Syndrome in the General Population. Curr Rheumatol Rep. 2022; 23(12):85. PMC: 8727975. DOI: 10.1007/s11926-021-01038-2. View

18.

Zheng M, Ambesi A, McKeown-Longo P . Role of TLR4 Receptor Complex in the Regulation of the Innate Immune Response by Fibronectin. Cells. 2020; 9(1). PMC: 7017243. DOI: 10.3390/cells9010216. View

19.

Lambert M, Brodovitch A, Mege J, Bertin D, Bardin N . Biological markers of high risk of thrombotic recurrence in patients with antiphospholipid syndrome: A literature review. Autoimmun Rev. 2024; 23(6):103585. DOI: 10.1016/j.autrev.2024.103585. View

20.

Caliz R, Atsumi T, Kondeatis E, Amengual O, Khamashta M, Vaughan R . HLA class II gene polymorphisms in antiphospholipid syndrome: haplotype analysis in 83 Caucasoid patients. Rheumatology (Oxford). 2001; 40(1):31-6. DOI: 10.1093/rheumatology/40.1.31. View